Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lyra Therapeutics ( (LYRA) ) just unveiled an update.
Lyra Therapeutics announced changes to its Board of Directors with the resignations of Michael Altman and Konstantin Poukalov. To maintain an equal balance among board classes, Maria Palasis, Ph.D. shifted from Class III to Class I, resulting in her resignation and immediate re-election, ensuring her service remained uninterrupted.
More about Lyra Therapeutics
YTD Price Performance: -96.15%
Average Trading Volume: 1,583,200
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.22M
For an in-depth examination of LYRA stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
